Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation & Amortization (CF) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $113360.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 25.08% to $113360.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $534809.0, a 10.98% decrease, with the full-year FY2024 number at $605637.0, up 142.65% from a year prior.
  • Depreciation & Amortization (CF) was $113360.0 for Q3 2025 at bioAffinity Technologies, roughly flat from $113229.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $154588.0 in Q1 2025 to a low of $773.0 in Q3 2022.
  • A 4-year average of $83105.9 and a median of $113229.0 in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 7347.48% in 2023, then fell 25.08% in 2025.
  • bioAffinity Technologies' Depreciation & Amortization (CF) stood at $7330.0 in 2022, then soared by 1929.84% to $148787.0 in 2023, then rose by 3.26% to $153632.0 in 2024, then decreased by 26.21% to $113360.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Depreciation & Amortization (CF) are $113360.0 (Q3 2025), $113229.0 (Q2 2025), and $154588.0 (Q1 2025).